Literature DB >> 17689653

A comparison of 3 criteria of oligohydramnios in identifying peripartum complications: a secondary analysis.

Julie M Johnson1, Suneet P Chauhan, Christopher S Ennen, Amy Niederhauser, Everett F Magann.   

Abstract

OBJECTIVE: The objective of the study was to ascertain the diagnostic accuracy of 3 criteria of oligohydramnios in identifying 4 peripartum complications. STUDY
DESIGN: The 3 definitions of oligohydramnios were amniotic fluid index (AFI) 5.0 cm or less and AFI <5% for gestational age (GA) using nomograms by Moore and Cayle or Magann et al. Likelihood ratio (LR) and guidelines by the Evidence-Based Medicine Working Group were used in the secondary analysis of previously published reports. AFI obtained during antepartum and intrapartum periods were analyzed separately.
RESULTS: The 95% confidence intervals for the prevalence of oligohydramnios using the 3 criteria are significantly different in the antepartum or intrapartum analysis. The LR was <6 for ante- and intrapartum AFI to identify cesarean delivery for nonreassuring fetal heart rate tracing, Apgar score 3 or less at 5 minutes, umbilical arterial pH <7.00, and newborns' weight 5% or less for GA.
CONCLUSION: The 3 criteria for determining the adequacy of amniotic fluid are not fungible, and they are not useful diagnostic tests for identifying peripartum complications because LR is <10.

Mesh:

Year:  2007        PMID: 17689653     DOI: 10.1016/j.ajog.2007.04.048

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Comparison of Perinatal and Maternal Outcomes in Borderline Versus Normal Amniotic Fluid Index in a Tertiary Care Center in Odisha: An Observational Prospective Study.

Authors:  Anuradha Vyas; G Prasanna; Sudarshan Dash; Sudhansu Rath
Journal:  Cureus       Date:  2021-11-24

2.  Evaluation of Maternal and Perinatal Outcomes of Induction in Borderline Oligohydramnios at Term.

Authors:  Setu Rathod; Sunil Kumar Samal
Journal:  J Clin Diagn Res       Date:  2017-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.